Recommendations for the detection of latent tuberculosis infection in patients with immune-mediated inflammatory diseases candidates for anti-TNF therapy may not be applicable in all settings

Rheumatol Int. 2022 Aug;42(8):1491-1492. doi: 10.1007/s00296-021-04963-8. Epub 2021 Aug 3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab
  • Humans
  • Infliximab
  • Latent Tuberculosis* / diagnosis
  • Latent Tuberculosis* / drug therapy
  • Tuberculin Test
  • Tumor Necrosis Factor Inhibitors / adverse effects
  • Tumor Necrosis Factor-alpha

Substances

  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab